Search

Your search keyword '"Gamma hydroxybutyrate"' showing total 31 results
Start Over Descriptor "Gamma hydroxybutyrate" Publisher plus media solutions
31 results on '"Gamma hydroxybutyrate"'

2. Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

Subjects
United States. Food and Drug Administration, Business planning, Gamma hydroxybutyrate, Cataplexy -- Drug therapy, Drug approval, Oral drugs, General interest, News, opinion and commentary
Abstract

DUBLIN: Jazz Pharmaceuticals plc has issued the following press release: Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav (calcium, magnesium, potassium, [...]

Published
2020

3. Avadel Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

Subjects
Narcolepsy, Gamma hydroxybutyrate, Web sites (World Wide Web), Cataplexy, General interest, News, opinion and commentary
Abstract

Chesterfield, MO: Avadel Pharmaceuticals has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Published
2020

4. Avadel Pharmaceuticals Announces Pricing of Public Offering

Subjects
United States. Securities and Exchange Commission, Stock offerings, Narcolepsy, Gamma hydroxybutyrate, Advertising executives, Securities offerings, Cataplexy, General interest, News, opinion and commentary
Abstract

DUBLIN: Avadel has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime [...]

Published
2020

5. Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Subjects
Clinical trials, Cataplexy -- Care and treatment, Gamma hydroxybutyrate, Narcolepsy, Company earnings/profit, General interest, News, opinion and commentary
Abstract

Dublin: Avadel Pharmaceuticals plc has issued the following news release: Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today positive topline data from its pivotal Phase 3 REST-ON trial assessing the safety [...]

Published
2020

6. Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Subjects
Clinical trials, Cataplexy -- Care and treatment, Medical research, Gamma hydroxybutyrate, Narcolepsy, General interest, News, opinion and commentary
Abstract

Chesterfield, MO: Avadel Pharmaceuticals has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for the [...]

Published
2020

7. Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

Subjects
United States. Food and Drug Administration, Cataplexy -- Drug therapy, Drug approval, Gamma hydroxybutyrate, Marketing, Music, Pharmaceutical industry, Narcolepsy, Novels, General interest, News, opinion and commentary, Xyrem (Medication)
Abstract

DUBLIN: Jazz Pharmaceuticals plc has issued the following news release: Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority [...]

Published
2020

9. Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds

Subjects
Private placements (Securities), Narcolepsy, Gamma hydroxybutyrate, Preferred stocks, Consultants (Persons), Cataplexy, General interest, News, opinion and commentary
Abstract

Chesterfield, MO: Avadel Pharmaceuticals has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Published
2020

10. Correspondence Letter to the ACMD to review GHB and GBL

Subjects
Gamma hydroxybutyrate, Lactones, Business, international
Abstract

London: UK Government has issued the following news release: Letter from the Home Secretary asking the Advisory Council on the Misuse of Drugs to review of the classification of GHB [...]

Published
2020

11. Avadel Pharmaceuticals Completes Enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Subjects
Clinical trials, Cataplexy -- Care and treatment, Gamma hydroxybutyrate, Narcolepsy, General interest, News, opinion and commentary
Abstract

DUBLIN: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Published
2019

12. Avadel Pharmaceuticals Receives U.S. FDA Approval for Nouress (AV001), a Cysteine Hydrochloride Injection for Treating Neonate Patients Requiring Total Parental Nutrition (TPN)

Subjects
United States. Food and Drug Administration, Cystine, Parenting, Newborn infants -- Food and nutrition, Cysteine, Drug approval, Thiols -- Intellectual property, Nutrition, Gamma hydroxybutyrate, Trademarks, Backup software, Narcolepsy, General interest, News, opinion and commentary
Abstract

Chesterfield, MO: Avadel Pharmaceuticals has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Published
2019

13. TILT Holdings Subsidiaries Jupiter Research and Blackbird Logistics to Exhibit at 2019 Marijuana Business Conference

Subjects
High technology industry -- Conferences, meetings and seminars, Marijuana -- Conferences, meetings and seminars -- Exhibitions, Gamma hydroxybutyrate, Technology, Backup software, Brand names, General interest, News, opinion and commentary
Abstract

CAMBRIDGE: TILT Holdings Inc. has issued the following press release: TILT Holdings Inc. ('TILT' or the 'Company') (CSE: TILT) (OTCQB: TLLTF), a foundational technology cannabis platform comprised of assets to [...]

Published
2019

14. Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Subjects
Clinical trials, Cataplexy -- Care and treatment, Gamma hydroxybutyrate, Narcolepsy, General interest, News, opinion and commentary
Abstract

IRELAND: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for the [...]

Published
2019

15. Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences

Subjects
Gamma hydroxybutyrate, Web sites (World Wide Web), Media executives, Narcolepsy, General interest, News, opinion and commentary
Abstract

DUBLIN: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating [...]

Published
2019

16. Avadel Announces Resignation of Kevin Kotler from Board of Directors

Subjects
Corporate directors -- Appointments, resignations and dismissals, Gamma hydroxybutyrate, Narcolepsy, General interest, News, opinion and commentary
Abstract

DUBLIN, Ireland: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, [...]

Published
2019

17. Avadel Pharmaceuticals Announces Pharmacokinetic (PK) Data for Once-Nightly FT218 that will be Included in an Oral Presentation at the World Sleep 2019 Congress on September 25th

Subjects
Gamma hydroxybutyrate, Medical centers, Sleep, Narcolepsy, General interest, News, opinion and commentary
Abstract

DUBLIN, Ireland: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, for [...]

Published
2019

18. Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019

Subjects
United States. Food and Drug Administration, Narcolepsy, Gamma hydroxybutyrate, Cataplexy, General interest, News, opinion and commentary
Abstract

DUBLIN: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing once-nightly sodium oxybate, FT218, for narcolepsy, today announced that the [...]

Published
2019

19. Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th

Subjects
Gamma hydroxybutyrate, Sleep, Conferences and conventions, Medical centers, Narcolepsy, General interest, News, opinion and commentary
Abstract

DUBLIN: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that Dr. Michael Thorpy, Director [...]

Published
2019

20. Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th

Subjects
Conferences and conventions, Gamma hydroxybutyrate, Web sites (World Wide Web), Media executives, Narcolepsy, General interest, News, opinion and commentary
Abstract

IRELAND: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, today [...]

Published
2019

21. Silver Airways Stands with The Bahamas with Resumed Flights and Relief Efforts

Subjects
Gamma hydroxybutyrate, Hurricanes, General interest, News, opinion and commentary
Abstract

FORT LAUDERDALE: Silver Airways has issued the following press release: Silver Airways, a long-standing partner and necessary air service link to the Bahamas, has resumed flights to all airports that [...]

Published
2019

22. Narcolepsy Drugs Market to Garner $5.36 Bn, Globally, by 2026 at 10.3% CAGR: Says Allied Market Research

Subjects
Drugs -- Market research -- Reports, Antidepressants -- Market research -- Reports, Narcolepsy -- Drug therapy -- Reports, Gamma hydroxybutyrate, Phenols (Class of compounds), Tricyclic antidepressants, Central nervous system stimulants, Central nervous system, Profits, Marketing research, General interest, News, opinion and commentary
Abstract

PORTLAND: Allied Market Research has issued the following news release: Allied Market Research recently published a report, titled, 'Narcolepsy Drugs Market by Disease Type (Daytime Extreme Sleepiness, Cataplexia, and Others) [...]

Published
2019

23. Avadel to Present New Data on Once-Nightly Sodium Oxybate at SLEEP 2019 Conference

Subjects
Conferences and conventions, Gamma hydroxybutyrate, Sleep, Narcolepsy, General interest, News, opinion and commentary
Abstract

DUBLIN: Avadel Pharmaceuticals plc has issued the following press release: Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced it will present two posters [...]

Published
2019

26. Quidnet (GHB) Ltd Net Asset Value(s)

Subjects
Gamma hydroxybutyrate, Stock exchanges, Foreign securities, Stock offerings, Valuation, General interest, News, opinion and commentary
Abstract

Isle of Man: The International Stock Exchange Group Limited has issued the following news release: ordinary GBP1.00 shares Currency NAV/Share Valuation Date GBP 1.43 31 Dec [...]

Published
2019

27. Quidnet (GHB) Ltd Annual report & accounts

Subjects
Gamma hydroxybutyrate, Corporate sponsorship, Stock exchanges, Foreign securities, Stock offerings, Financial statements, General interest, News, opinion and commentary
Abstract

Isle of Man: The International Stock Exchange Group Limited has issued the following news release: Annual Report and Audited Financial Statements Quidnet (GHB) Ltd announces the release of its Annual [...]

Published
2019

28. Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program

Subjects
Narcolepsy -- Care and treatment, Corporate reorganizations, Health, Gamma hydroxybutyrate, Cataplexy, Company restructuring/company reorganization, Company organization, General interest, News, opinion and commentary, Noctiva (Medication)
Abstract

DUBLIN: Avadel Pharmaceuticals plc has issued the following news release:Avadel Pharmaceuticals plc (Nasdaq: AVDL), today announced a corporate restructuring to assure the financial health required to maximize the value of [...]

Published
2019

29. Swiss Official Gazette of Commerce notice: HR of Canton Schwyz: Change GHB Ground Engineering AG, Morschach, to date Stones HR02-1004516239

Subjects
Gamma hydroxybutyrate, General interest, News, opinion and commentary
Abstract

Bern: Swiss Official Gazette of Commerce has issued the following notice:Change GHB Ground Engineering AG, Morschach, to date StonesGHB Ground Engineering AGSchool Street 116443 MorschachTo dateBahnhofstrasse 326422 stonesUID: CHE242729065Legal form: [...]

Published
2018

30. Saliva test to detect GHB and alcohol poisonings

Subjects
College faculty, Gamma hydroxybutyrate, Poisoning, Universities and colleges, Business, international
Abstract

London: Institute Of Physics has issued the following news release:The saliva-based test offers the potential to screen for poisons commonly associated with the cheap or imitation manufacture of alcohol, and [...]

Published
2016

31. Saliva test to detect GHB and alcohol poisonings

Subjects
Gamma hydroxybutyrate, Poisoning, Scientists, Universities and colleges, Business, international, Loughborough University
Abstract

London: Institute Of Physics has issued the following news release:Scientists working at Loughborough University, UK, and the University of Cordoba, Spain, have developed a new method for the rapid diagnosis [...]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results